Pennsylvania Senate Bill SB607

Pennsylvania 2023-2024 Regular Session

• Introduced: 4/28/23
• Refer: 4/28/23
• Refer: 5/8/23
• Report Pass: 6/19/23
• Engrossed: 6/19/23
• Refer: 6/20/23
• Refer: 11/15/23
• Report Pass: 12/11/23
• Enrolled: 12/12/23
• Chaptered: 12/14/23
• Passed: 12/14/23

Caption

In pharmaceutical assistance for the elderly, further providing for determination of eligibility.

Impact

By extending eligibility in the PACENET and PACE programs, SB607 aims to mitigate the financial burden on seniors who might otherwise lose assistance due to cost-of-living increases. This change is significant as it recognizes the challenges that many elderly individuals face with rising living costs while ensuring they maintain access to essential pharmaceutical support. If enacted, it would protect vulnerable populations from being disqualified from these assistance programs solely based on income adjustments from Social Security.

Summary

Senate Bill 607 focuses on the eligibility requirements for pharmaceutical assistance programs in Pennsylvania, particularly the PACE and PACENET programs. This legislation amends the existing State Lottery Law to provide continued eligibility for individuals enrolled in these programs if their income exceeds the maximum limit solely due to a Social Security cost-of-living adjustment. The bill highlights a commitment to ensuring that our elderly population continues to have access to necessary medications despite potential increases in income from social security adjustments.

Sentiment

The sentiment surrounding SB607 appears to be largely supportive among advocacy groups and stakeholders focused on elderly health issues. There is recognition that the bill addresses a critical need to adapt assistance programs in response to changes in living costs, which are particularly impactful for older adults. Proponents contend that this legislation is a necessary adjustment in light of economic realities faced by the elderly.

Contention

While the bill has received support, there may still be contention regarding its long-term funding implications and the sustainability of keeping income limits flexible. Critics may be concerned about how these adjustments align with the overall budget of the state's pharmaceutical assistance programs, particularly given demographic shifts with an aging population. Addressing the balance between fiscal responsibility and the need for social support in the context of rising costs will likely be a focal point in further discussions.